GlobeNewswire by notified

Kalera, Global Leader in Indoor Vertical Farming, Turns New Leaf with Branding Relaunch

Share

Rebrand to attract growing global market with a new visual identity

ORLANDO, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Kalera, one of the world’s leading hydroponic indoor vertical farmers, announces its rebrand featuring minimalistic and fresh design elements to complement the company’s premium, clean lettuce and microgreen varieties. The rebrand features a new logo and website design that will attract the general global consumer.

“Our new logo’s minimalistic design makes it timeless in nature and will stand out on shelves,” said Henner Schwarz, Chief Commercial Officer for Kalera. “It is recognizable yet not loud or intrusive. It provides a podium for the true heroes of our story: our product and our people.”

Kalera sustainably grows lettuce and microgreen varieties year-round through advanced proprietary technology and plant and seed science that has less environmental impact than traditional field farming.

“Kalera began with a clear goal: to sustainably grow cleaner and healthier greens accessible for all. Our fresh visual identity accurately reflects our mission to provide the freshest greens globally,” added Aric Nissen, Kalera’s Chief Marketing Officer. “The new wave of farming is here, and Kalera is leading the way through innovation and creativity.”

Kalera lettuce and microgreen varieties are nutrient rich and free of harmful chemicals or pesticides. The rebrand reflects these product attributes, with pure, fresh design features that further publicize Kalera produce as clean.

“While we farm locally, we inspire change globally. We represent a cleaner, greener way of farming, and consumers are connected to the ideas and purpose behind the new Kalera brand,” said Schwarz. “Offering a brand that clearly reflects our mission of providing clean produce is imperative, as is a brand that is modern and universal, especially as Kalera continues to expand operations globally.”

Beyond a new logo, the rebrand will renew Kalera’s brand messaging across all marketing channels and within its portfolio of five large-scale global farms. The company will debut new branded packaging and a revolutionizing tagline on June 1, 2022. “The early reaction from our consumers and retailers is beyond fantastic and we can’t wait to show this work publicly,” said Nissen.

In addition to a farm currently operating in Kuwait, Kalera recently opened its fourth large-scale U.S. farm in Denver, with first harvest slated for May. The company has an additional five large-scale vertical farms under construction in Seattle; Columbus, Ohio; Honolulu; St. Paul, Minnesota; and Singapore.

For more information on Kalera, visit kalera.com

About Kalera:
Kalera is a vertical farming company headquartered in Orlando, Florida. Kalera uses proprietary technology and plant and seed science to sustainably grow year-round, local, non-GMO leafy greens that are nutrient-rich and free of harmful chemicals or pesticides. It has spent several years optimizing plant nutrient formulas and developing an advanced automation and data acquisition system with Internet of Things, cloud, big data analytics and artificial intelligence capabilities. Kalera currently operates farms in the US (Orlando, Atlanta, Houston and Denver) as well as in Munich and Kuwait. Additional farms are in development. More information is available at www.kalera.com.

Contact:
Kathleen Komarzec
kkomarzec@lambert.com
(616) 916-4092

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/55f4fe2e-a1b2-4be9-949d-583a8a0c3ec9

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mandalay Resources Corporation Announces the Results of Its Annual General Meeting of Shareholders25.5.2022 23:32:49 CEST | Press release

TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) held today virtually. All the resolutions presented at the Meeting were approved by the shareholders, with the votes cast by proxy representing 67.63% of the total shares outstanding as of the record date. Election of Directors The number of directors was fixed at seven members and each of the seven nominees listed in the Company’s Management Information Circular dated April 14, 2022, were re-elected to the Company’s Board of Directors. Abraham Jonker remains the lead independent director and Bradford Mills continues as Chair. Results of the votes cast by proxy are set out below. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94

Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress25.5.2022 22:01:00 CEST | Press release

Celebrating EULAR’s 75thanniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium;25 May 2022, 22.01CET;Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark. The broad range of abstracts include trial data analyses supporting the efficacy and safety profile of filgotinib andreal-world clinical data around alignment of prescribing between physicians and rheumatoid arthritis (RA) patients. Galapagos is also hosting a hybrid symposium: “Evolving patient care in RA: Can JAK inhibitors meet patient and physician expectations for RA treatment?”, which will include a discussion focused on aligning physician and patient treatment goals, looking at what is meant by ‘comprehensive care’ and how to ensure that people living with RA are part of treatment and care goal setting. A meet-the-expert session, “Patient-centred care in RA: cutting through th

trivago N.V. Announces Annual General Meeting of Shareholders25.5.2022 21:39:06 CEST | Press release

trivago N.V. (NASDAQ: TRVG) announced today that its annual general meeting of shareholders will be held on June 30, 2022 at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands. The meeting will start at 3:00 p.m. CEST. The convening notice and explanatory notes for the general meeting are available free of charge in the Investor Relations section of trivago N.V.'s corporate website at ir.trivago.com. About trivago N.V. trivago is a leading global hotel search platform focused on reshaping the way travelers search for and compare hotels and alternative accommodations. Incorporated in 2005 in Düsseldorf, Germany, the platform allows travelers to make informed decisions by personalizing their hotel search and providing them access to a deep supply of hotel information and prices. trivago enables its advertisers to grow their businesses by providing access to a broad audience of travelers via its websites and apps. As of March 31, 2022, trivago has est

Correction: Changes in Nokia Corporation's own shares25.5.2022 19:20:00 CEST | Press release

Nokia Corporation Stock Exchange Release 25 May 2022 at 20:20 EEST Correction: Changes in Nokia Corporation's own shares Espoo, Finland – This is a correction to "Changes in Nokia Corporation's own shares" stock exchange release that was published today at 19:30 EEST. A total of 183 965 Nokia shares (NOKIA) held by the company were today transferred without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 61 262 561. This version is otherwise identical but now includes an updated total number of Nokia shares transferred (incorrect number was 188 636). About Nokia At Nokia, we create technology that helps the world act together. As a trusted partner for critical

Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy25.5.2022 18:45:00 CEST | Press release

Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 years UV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint inhibition Oslo, 25 May2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of long-term follow-up data on UV1 in the Journal for ImmunoTherapy of Cancer (JITC). The data show that dynamic UV1 specific immune responses last up to 7.5 years, are associated with longer survival and are enhanced when UV1 is used in combinations with checkpoint inhibitors. “It is important to be able to share this validating data with our research and clinical colleagues through JITC. The data demonstrate highly durable UV1-induced immune responses that are associated with substantially longer overall survival and boosted by checkpoint inhibitors. This is strong support for Ultimovacs’ broad Phase II program combining UV1